Yeon Suk Jung1, Jung Hwa Park1,2, Hyunha Kim1,2, So Young Kim3, Ji Young Hwang1,2, Ki Whan Hong4, Sun Sik Bae4, Byung Tae Choi1,2,3, Sae-Won Lee1,2, Hwa Kyoung Shin1,2,3. 1. Korean Medical Science Research Center for Healthy-Aging, Pusan National University, Yangsan, Gyeongnam 626-870, Republic of Korea. 2. Department of Korean Medical Science, School of Korean Medicine, Pusan National University, Yangsan, Gyeongnam 626-870, Republic of Korea. 3. Division of Meridian and Structural Medicine, School of Korean Medicine, Pusan National University, Yangsan, Gyeongnam 626-870, Republic of Korea. 4. Department of Pharmacology, School of Medicine, Pusan National University, Yangsan, Gyeongnam 626-870, Republic of Korea.
Abstract
AIM: Increasing evidence suggests that probucol, a lipid-lowering agent with anti-oxidant activities, may be useful for the treatment of ischemic stroke with hyperlipidemia via reduction in cholesterol and neuroinflammation. In this study we examined whether probucol could protect against brain ischemic injury via anti-neuroinflammatory action in normal and hyperlipidemic mice. METHODS: Primary mouse microglia and murine BV2 microglia were exposed to lipopolysaccharide (LPS) for 3 h, and the release NO, PGE2, IL-1β and IL-6, as well as the changes in NF-κB, MAPK and AP-1 signaling pathways were assessed. ApoE KO mice were fed a high-fat diet containing 0.004%, 0.02%, 0.1% (wt/wt) probucol for 10 weeks, whereas normal C57BL/6J mice received probucol (3, 10, 30 mg·kg(-1)·d(-1), po) for 4 d. Then all the mice were subjected to focal cerebral ischemia through middle cerebral artery occlusion (MCAO). The neurological deficits were scored 24 h after the surgery, and then brains were removed for measuring the cerebral infarct size and the production of pro-inflammatory mediators. RESULTS: In LPS-treated BV2 cells and primary microglial cells, pretreatment with probucol (1, 5, 10 μmol/L) dose-dependently inhibited the release of NO, PGE2, IL-1β and IL-6, which occurred at the transcription levels. Furthermore, the inhibitory actions of probucol were associated with the downregulation of the NF-κB, MAPK and AP-1 signaling pathways. In the normal mice with MCAO, pre-administration of probucol dose-dependently decreased the infarct volume and improved neurological function. These effects were accompanied by the decreased production of pro-inflammatory mediators (iNOS, COX-2, IL-1, IL-6). In ApoE KO mice fed a high-fat diet, pre-administration of 0.1% probucol significantly reduced the infarct volume, improved the neurological deficits following MCAO, and decreased the total- and LDL-cholesterol levels. CONCLUSION: Probucol inhibits LPS-induced microglia activation and ameliorates cerebral ischemic injury in normal and hyperlipidemic mice via its anti-neuroinflammatory actions, suggesting that probucol has potential for the treatment of patients with or at risk for ischemic stroke and hyperlipidemia.
AIM: Increasing evidence suggests that probucol, a lipid-lowering agent with anti-oxidant activities, may be useful for the treatment of ischemic stroke with hyperlipidemia via reduction in cholesterol and neuroinflammation. In this study we examined whether probucol could protect against brain ischemic injury via anti-neuroinflammatory action in normal and hyperlipidemic mice. METHODS: Primary mouse microglia and murine BV2 microglia were exposed to lipopolysaccharide (LPS) for 3 h, and the release NO, PGE2, IL-1β and IL-6, as well as the changes in NF-κB, MAPK and AP-1 signaling pathways were assessed. ApoE KO mice were fed a high-fat diet containing 0.004%, 0.02%, 0.1% (wt/wt) probucol for 10 weeks, whereas normal C57BL/6J mice received probucol (3, 10, 30 mg·kg(-1)·d(-1), po) for 4 d. Then all the mice were subjected to focal cerebral ischemia through middle cerebral artery occlusion (MCAO). The neurological deficits were scored 24 h after the surgery, and then brains were removed for measuring the cerebral infarct size and the production of pro-inflammatory mediators. RESULTS: In LPS-treated BV2 cells and primary microglial cells, pretreatment with probucol (1, 5, 10 μmol/L) dose-dependently inhibited the release of NO, PGE2, IL-1β and IL-6, which occurred at the transcription levels. Furthermore, the inhibitory actions of probucol were associated with the downregulation of the NF-κB, MAPK and AP-1 signaling pathways. In the normal mice with MCAO, pre-administration of probucol dose-dependently decreased the infarct volume and improved neurological function. These effects were accompanied by the decreased production of pro-inflammatory mediators (iNOS, COX-2, IL-1, IL-6). In ApoE KO mice fed a high-fat diet, pre-administration of 0.1% probucol significantly reduced the infarct volume, improved the neurological deficits following MCAO, and decreased the total- and LDL-cholesterol levels. CONCLUSION:Probucol inhibits LPS-induced microglia activation and ameliorates cerebral ischemic injury in normal and hyperlipidemic mice via its anti-neuroinflammatory actions, suggesting that probucol has potential for the treatment of patients with or at risk for ischemic stroke and hyperlipidemia.
Authors: Ying Tung Sia; Thomas G Parker; Peter Liu; James N Tsoporis; Albert Adam; Jean L Rouleau Journal: J Am Coll Cardiol Date: 2002-01-02 Impact factor: 24.094
Authors: Xiaoling Li; Kathleen K Blizzard; Zhiyuan Zeng; A Courtney DeVries; Patricia D Hurn; Louise D McCullough Journal: Exp Neurol Date: 2004-05 Impact factor: 5.330
Authors: Joachim Röther; Mark J Alberts; Emmanuel Touzé; Jean-Louis Mas; Michael D Hill; Patrik Michel; Deepak L Bhatt; Franz T Aichner; Shinya Goto; Masayasu Matsumoto; E Magnus Ohman; Yasushi Okada; Shinichiro Uchiyama; Ralph D'Agostino; Alan T Hirsch; Peter W F Wilson; P Gabriel Steg Journal: Cerebrovasc Dis Date: 2008-03-13 Impact factor: 2.762
Authors: Ben J Wu; Krishna Kathir; Paul K Witting; Konstanze Beck; Katherine Choy; Cheng Li; Kevin D Croft; Trevor A Mori; David Tanous; Mark R Adams; Antony K Lau; Roland Stocker Journal: J Exp Med Date: 2006-04-10 Impact factor: 14.307
Authors: Cristine de Paula Nascimento-Castro; Ana Claudia Wink; Victor Silva da Fônseca; Claudia Daniele Bianco; Elisa C Winkelmann-Duarte; Marcelo Farina; Ana Lúcia S Rodrigues; Joana Gil-Mohapel; Andreza Fabro de Bem; Patricia S Brocardo Journal: Neural Plast Date: 2018-08-14 Impact factor: 3.599